UNSPSC 51287011: Etocarlide

This classification denotes an antitubercular agent with the molecular formula C17H20N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46V3V5EQAM, chemically known as 4,4-diethoxythiocarbanilide but more generally known as etocarlide, which bears US NIH Compound Identifier 667483. European Medicines Agency schedules Etocarlide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07314MIG.

The term ETOCARLIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). ETOCARLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S=C(NC1CCC(OCC)CC1)NC1CCC(OCC)CC1.

UNSPSC 51287011 Etocarlide, a Commodity code, does not align with the state and local procurement opportunities recently tagged under it. The code nominally describes etocarlide, a radiographic contrast agent used in medical imaging, yet recent solicitations under this code cover naloxone, pharmaceutical supply chain management, medical and first aid supplies for emergency response, and generic pharmaceuticals through cooperative purchasing — none of which involve etocarlide or radiographic contrast media. The mismatch suggests either miscoding in source systems or a data-classification artifact rather than genuine demand for etocarlide itself in state and local procurement.

The issuing bodies soliciting under this code span diverse public-sector categories: Seminole County, Florida (county health); the City of Tampa (municipal fire department); Texas Health and Human Services Commission (state department); and the Minnesota Multistate Cooperative Purchasing Alliance administering cooperative purchasing for multiple states. Recent activity includes an IFB from Seminole County for naloxone and drug deactivation systems (due July 26, 2023, though posted June 30, 2026—suggesting a data-integrity issue), an RFI from Texas HHS regarding direct-to-manufacturer prescription programs (due April 3, 2026), an IFB from Tampa for medical and first aid supplies estimated at $700,000 (due March 13, 2026, with SLBE set-aside), and an RFP from MMCAP for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon (due March 26, 2026). The geographic spread includes Florida, Texas, Minnesota, and Oregon. Given the disconnect between the code's nominal scope and the actual opportunities tagged to it, this code shows little relevant recent activity for etocarlide procurement specifically.